Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

Abroad (travel likely)RecruitingPHASE1

Conditions

Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

MD Anderson, Houston, Texas, United States
Contact: Study coordinator (Nicholas Short) · nshort@mdanderson.org · 1-877-632-6789

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

Myeloid Malignancy · Acute Myeloid Leukemia · Myelodysplastic Syndromes

Abroad (travel likely)RecruitingPHASE1

Minneapolis, United States

First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)

R/R AML · R/R HR-MDS · Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Aarhus, Denmark · Copenhagen, Denmark

Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

AML · Refractory/Relapse Acute Myeloid Leukemia

Abroad (travel likely)RecruitingPHASE1

Beijing, China

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Acute Myeloid Leukemia · Mixed Lineage Leukemia Gene Mutation · Refractory AML

Abroad (travel likely)RecruitingPHASE1

Phoenix, United States · La Jolla, United States